Cargando…

Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro

Oxaliplatin is a platinum-based antineoplastic drug commonly used for treating colorectal, gastric, and pancreatic cancer. However, it frequently causes peripheral neuropathy as dose-limiting toxicity and is lacking a strategy for prevention. Alogliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shigematsu, Nao, Kawashiri, Takehiro, Kobayashi, Daisuke, Shimizu, Shiori, Mine, Keisuke, Hiromoto, Shiori, Uchida, Mayako, Egashira, Nobuaki, Shimazoe, Takao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174301/ https://www.ncbi.nlm.nih.gov/pubmed/32317735 http://dx.doi.org/10.1038/s41598-020-62738-w

Ejemplares similares

Omeprazole Suppresses Oxaliplatin-Induced Peripheral Neuropathy in a Rodent Model and Clinical Database
por: Mine, Keisuke, et al.
Publicado: (2022)

Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence
por: Kawashiri, Takehiro, et al.
Publicado: (2021)

Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome
por: Hiromoto, Shiori, et al.
Publicado: (2021)

Oral administration of Cystine and Theanine ameliorates oxaliplatin-induced chronic peripheral neuropathy in rodents
por: Kawashiri, Takehiro, et al.
Publicado: (2020)

Inhibitory Effect of α1 Receptor Antagonists on Paclitaxel-Induced Peripheral Neuropathy in a Rodent Model and Clinical Database
por: Mori, Kohei, et al.
Publicado: (2022)

Preclinical and Clinical Evidence of Therapeutic Agents for Paclitaxel-Induced Peripheral Neuropathy
por: Kawashiri, Takehiro, et al.
Publicado: (2021)

Exenatide Facilitates Recovery from Oxaliplatin-Induced Peripheral Neuropathy in Rats
por: Fujita, Shunsuke, et al.
Publicado: (2015)

Pathological Mechanisms and Preventive Strategies of Oxaliplatin-Induced Peripheral Neuropathy
por: Egashira, Nobuaki
Publicado: (2021)

Involvement of spinal NR2B-containing NMDA receptors in oxaliplatin-induced mechanical allodynia in rats
por: Mihara, Yuki, et al.
Publicado: (2011)

Inhibition of Ca(2+)/Calmodulin-dependent protein kinase II reverses oxaliplatin-induced mechanical allodynia in Rats
por: Shirahama, Masafumi, et al.
Publicado: (2012)

L type Ca(2+ )channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 overexpression in rats
por: Kawashiri, Takehiro, et al.
Publicado: (2012)

Excessive spinal glutamate transmission is involved in oxaliplatin-induced mechanical allodynia: a possibility for riluzole as a prophylactic drug
por: Yamamoto, Shota, et al.
Publicado: (2017)

“POLAR-izing” Findings From Trials of Neuroprotection for Oxaliplatin Neuropathy
por: Teng, Christina, et al.
Publicado: (2022)

The Combination of Zinc and Melatonin Enhanced Neuroprotection and Attenuated Neuropathy in Oxaliplatin-Induced Neurotoxicity
por: Ali, Mayyadah, et al.
Publicado: (2022)

Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy
por: Yamamoto, Shota, et al.
Publicado: (2021)

Effects of metformin and alogliptin on body composition in people with type 2 diabetes
por: Takeshita, Yumie, et al.
Publicado: (2018)

Neuroprotective Effects of an Aqueous Extract of Forsythia viridissima and Its Major Constituents on Oxaliplatin-Induced Peripheral Neuropathy
por: Yi, Jin-Mu, et al.
Publicado: (2019)

Topical Delivery of Four Neuroprotective Ingredients by Ethosome-Gel: Synergistic Combination for Treatment of Oxaliplatin-Induced Peripheral Neuropathy
por: Lin, Hong-mei, et al.
Publicado: (2020)

Management of oxaliplatin-induced peripheral neuropathy
por: Saif, M Wasif, et al.
Publicado: (2005)

Oxaliplatin-Induced Neuropathy in Colorectal Cancer
por: Weickhardt, Andrew, et al.
Publicado: (2011)

Immunohistochemical Pharmacokinetics of the Anti-diabetes Drug Alogliptin in Rat Kidney and Liver
por: Yamamoto, Yutaro, et al.
Publicado: (2020)

Drug Repositioning for the Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Mechanism- and Screening-Based Strategy
por: Yamamoto, Shota, et al.
Publicado: (2021)

Efficacy of Goshajinkigan for Oxaliplatin-Induced Peripheral Neuropathy in Colorectal Cancer Patients
por: Yoshida, Naohisa, et al.
Publicado: (2013)

Alogliptin benzoate for management of type 2 diabetes
por: Saisho, Yoshifumi
Publicado: (2015)

Efficacy and safety of alogliptin in a pediatric patient with maturity-onset diabetes of the young type 1
por: Tonouchi, Ryosuke, et al.
Publicado: (2017)

A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes
por: Shigematsu, Erina, et al.
Publicado: (2017)

Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy
por: Cavaletti, Guido, et al.
Publicado: (2020)

Platinum accumulation in oxaliplatin‐induced peripheral neuropathy
por: Wei, Guoli, et al.
Publicado: (2021)

Semi-Mechanism-Based Pharmacokinetic-Toxicodynamic Model of Oxaliplatin-Induced Acute and Chronic Neuropathy
por: Kobuchi, Shinji, et al.
Publicado: (2020)

Antioxidant and Neuroprotective Effect of a Grape Pomace Extract on Oxaliplatin-Induced Peripheral Neuropathy in Rats: Biochemical, Behavioral and Histopathological Evaluation
por: Bekiari, Chryssa, et al.
Publicado: (2022)

Subjective and objective assessment of oxaliplatin-induced peripheral neuropathy
por: Yoshida, Yoichiro, et al.
Publicado: (2015)

Astragali radix: could it be an adjuvant for oxaliplatin-induced neuropathy?
por: Di Cesare Mannelli, Lorenzo, et al.
Publicado: (2017)

Differences in recognition of similar medication names between pharmacists and nurses: a retrospective study
por: Tsuji, Toshikazu, et al.
Publicado: (2015)

A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy
por: Kim, Su-Hyun, et al.
Publicado: (2018)

Comprehensive Efficacy of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin in Practical Clinical Settings: A Prospective Multi-Center Interventional Observational Study
por: Takamiya, Yosuke, et al.
Publicado: (2020)

Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Andukuri, Radha, et al.
Publicado: (2009)

Liquid Chromatographic Determination of Alogliptin in Bulk and in its Pharmaceutical Preparation
por: El-Bagary, Ramzia I., et al.
Publicado: (2012)

Enhancing Pancreatic Beta-Cell Regeneration In Vivo with Pioglitazone and Alogliptin
por: Yin, Hao, et al.
Publicado: (2013)

Alogliptin-Induced Minimal Change Nephrotic Syndrome and Interstitial Nephritis
por: Shima, Hisato, et al.
Publicado: (2019)

Necrotizing Pancreatitis Secondary to Hydrochlorothiazide and Alogliptin: A Case Report
por: Del Rio, Teresa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0uuqqqumsq6m1or57t4m82phvi